NSC 3852

Key Product Details

Product Description

NSC 3852 is a histone deacetylase inhibitor. Causes cell differentiation and antiproliferative activity in MCF-7 human breast cancer cells in vitro and displays antitumor activity in vivo. Also exhibits antiproliferative, proapoptotic and differentiation effects in pediatric acute myeloid leukemia cell lines.

Product Specifications for NSC 3852

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for NSC 3852

The following data is based on the product molecular weight 174.16.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	5.74 mL	28.71 mL	57.42 mL
5 mM	1.15 mL	5.74 mL	11.48 mL
10 mM	0.57 mL	2.87 mL	5.74 mL
50 mM	0.11 mL	0.57 mL	1.15 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Martirosyan Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. J.Pharmacol.Exp.Ther. 2006 PMID: 16497787
• Wiggers Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia. Pediatr.Blood Cancer. 2019 PMID: 31044544
• Martirosyan Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model. Biochem.Pharmacol. 2004 PMID: 15450938

Product Documents for NSC 3852